Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml
Synlett 2016; 27(17): 2489-2493
DOI: 10.1055/s-0035-1562690
DOI: 10.1055/s-0035-1562690
letter
Stereoselective Michael Halogenation Initiated Ring Closure (MHIRC) Synthesis of Spirocyclopropanes from Benzylidenemalononitriles and 3-Arylisoxazol-5(4H)-ones
Further Information
Publication History
Received: 18 April 2016
Accepted after revision: 22 June 2016
Publication Date:
19 July 2016 (online)
Abstract
The new chemical cascade reaction was found: the direct formation of substituted 4-oxo-2,7-diaryl-5-oxa-6-azaspiro[2.4]hept-6-ene-1,1-dicarbonitriles from benzylidenemalononitriles and 3-aryl-2-isoxazol-5(4H)-ones. The action of bromine on the equimolar mixture of benzylidenemalononitrile and 3-aryl-2-isoxazol-5(4H)-one in the basic alcohol solution results in stereoselective formation of spirobicycle containing the 2-isoxazolin-5-one and the cyclopropane fragments in 53–92% yields. Thus, the new simple and efficient ‘one-pot’ approach to substituted (2R*,3R*)-4-oxo-2,7-diaryl-5-oxa-6-azaspiro[2.4]hept-6-ene-1,1-dicarbonitriles was found directly from simple and reasonable starting compounds as benzylidenemalonitriles and 3-aryl-2-isoxazol-5(4H)-ones.
Key words
MHIRC reaction - cyclopropane formation - 3-aryl-2-isoxazolin-5(4H)-ones - benzylidenemalononitriles - 5-oxa-6-azaspiro[2.4]hept-6-enesSupporting Information
- Supporting information for this article is available online at http://dx.doi.org/10.1055/s-0035-1562690.
- Supporting Information
-
References and Notes
- 1a Katritzky AR, Rees CW, Scriven EF. V. Comprehensive Heterocyclic Chemistry II . Pergamon Press; Oxford: 1996
- 1b Katritzky AR, Ramsden CA, Scriven EF. V, Taylor RJ. K. Comprehensive Heterocyclic Chemistry III . Pergamon Press; Oxford: 2008
- 2a Lakhvich EV. K. F. A, Akhrem AA. Chem. Heterocycl. Compd. 1989; 25: 359
- 2b Sperry JB, Wright DL. Curr. Opin. Drug Discovery Dev. 2005; 8: 723
- 3a Tang M, Odejinmi SI, Alette YM, Vankayalapati H, Lai K. Bioorg. Med. Chem. 2011; 19: 5886
- 3b Hallenbach W, Guth O, Seitz T, Wroblowsky H.-J, Desbordes P, Wachendorff-Neumann U, Dahmen P, Voerste A, Lösel P, Malsam O, Rama R, Hadano H. US 20120100989, 2012
- 3c Ishioka T, Tanatani A, Nagasawa K, Hashimoto Y. Bioorg. Med. Chem. Lett. 2003; 13: 2655
- 4a Donaldson WA. Tetrahedron 2001; 57: 8589
- 4b Brandt W, Thiemann T. Chem. Rev. 2003; 103: 1625
- 4c Chen DY.-K, Pouwerb RH, Richard J.-A. Chem. Soc. Rev. 2012; 41: 4631
- 5a Graham DW, Ashton WT, Barash L, Brown JE, Brown RD, Canning LF, Chen A, Springer JP, Rogers EF. J. Med. Chem. 1987; 30: 1074
- 5b Salaün J, Baird MS. Curr. Med. Chem. 1995; 2: 511
- 5c Boger DL, Hughes TV, Hedrick MP. J. Org. Chem. 2001; 66: 2207
- 5d Yamaguchi K, Kazuta Y, Hirano K, Yamada S, Matsuda A, Shuto S. Bioorg. Med. Chem. 2008; 16: 8875
- 6a Roman DL, Talbot JN, Roof RA, Sunahara RK, Traynor JR, Neubig RR. Mol. Pharmacol. 2007; 71: 169
- 6b Henry P (Boston Biomedical Research Institute) WO 2006079057, 2006
- 7a Elinson MN, Lizunova TL, Dekaprilevich MO, Struchkov YT, Nikishin GI. Mendeleev Commun. 1993; 192
- 7b Vereshchagin AN, Elinson MN, Dorofeeva EO, Demchuk DV, Bushmarinov IS, Goloveshkin AS, Nikishin GI. Tetrahedron 2013; 69: 5234
- 7c Elinson MN, Feducovich SK, Vereshchagin AN, Dorofeev AS, Dmitriev DE, Nikishin GI. Russ. Chem. Bull. Int. Ed. 2003; 52: 2235
- 7d Elinson MN, Feducovich SK, Zaimovskaya TA, Vereshchagin AN, Gorbunov SV, Nikishin GI. Russ. Chem. Bull. Int. Ed. 2005; 54: 1593
- 7e Elinson MN, Feducovich SK, Starikova ZA, Vereshchagin AN, Belyakov PA, Nikishin GI. Tetrahedron 2006; 62: 3989
- 7f Vereshchagin AN, Elinson MN, Stepanov NO, Nikishin GI. Mendeleev Commun. 2009; 19: 324
- 7g Vereshchagin AN, Elinson MN, Zaimovskaya TA, Nikishin GI. Tetrahedron 2008; 64: 9766
- 7h Elinson MN, Vereshchagin AN, Stepanov NO, Ilovaisky AI, Vorontsov AY, Nikishin GI. Tetrahedron 2009; 65: 6057
- 7i Vereshchagin AN, Elinson MN, Egorov MP. RSC Adv. 2015; 5: 98522
- 8a Laroche C, Behr J.-B, Szymoniak J, Bertus P, Schutz C, Vogel P, Plantier-Royon R. Bioorg. Med. Chem. 2006; 14: 4047
- 8b Sandanayaka VP, Prashad AS, Yang Y, Williamson RT, Lin YI, Mansour TS. J. Med. Chem. 2003; 46: 2569
- 8c Jiang T, Kuhen KL, Wolff K, Yin H, Bieza K, Caldwell J, Bursulaya B, Wub TY.-H, He Y. Bioorg. Med. Chem. Lett. 2006; 16: 2105
- 8d Jiang T, Kuhen KL, Wolff K, Yin H, Bieza K, Caldwell J, Bursulaya B, Tuntland T, Zhang K, Karanewsky D, He Y. Bioorg. Med. Chem. Lett. 2006; 16: 2109
- 9a Elinson MN, Vereshchagin AN, Stepanov NO, Zaimovskaya TA, Merkulova VM, Vorontsov AY, Nikishin GI. Tetrahedron Lett. 2010; 51: 428
- 9b Dorofeeva EO, Elinson MN, Vereshchagin AN, Stepanov NO, Bushmarinov IS, Belyakov PA, Sokolova OO, Nikishin GI. RSC Adv. 2012; 2: 4444
- 9c Vereshchagin AN, Elinson MN, Dorofeeva EO, Stepanov NO, Zaimovskaya TA, Nikishin GI. Tetrahedron 2013; 69: 1945
- 9d Elinson MN, Vereshchagin AN, Tretyakova EO, Bushmarinov IS, Nikishin GI. Synthesis 2011; 3015
- 9e Elinson MN, Dorofeeva EO, Vereshchagin AN, Nasybullin RF, Egorov MP. Catal. Sci. Technol. 2015; 5: 2384
- 9f Vereshchagin AN, Elinson MN, Dorofeeva EO, Nasybullin RF, Bushmarinov IS, Goloveshkin AS, Egorov MP. Electrochim. Acta 2015; 165: 116
- 9g Elinson MN, Dorofeeva EO, Vereshchagin AN, Korshunov AD, Egorov MP. Res. Chem. Intermed. 2016; 42: 2191
- 10a Vereshchagin AN, Elinson MN, Korshunov AD, Korolev VA, Egorov MP. Heterocycl. Commun. 2015; 21: 355
- 10b Vereshchagin AN, Elinson MN, Korshunov AD, Egorov MP. Mendeleev Commun. 2016; 26: 19
- 12 4-Oxo-2,7-diaryl-5-oxa-6-azaspiro[2.4]hept-6-ene-1,1-dicarbonitriles 3a-j; General Procedure To a 15 mL EtOH suspension of benzylidenemalononitrile 1 (4 mmol) and 3-aryl-2-isoxazol-5(4H)-one 2 (4 mmol) in a 50 mL beaker, sodium ethylate (4.8 mmol) in alcohol (5 mL) was poured. Then bromine (4 mmol) was added without cooling. The mixture was magnetically stirred at room temperature for 2 h. Then reaction mixture was cooled to –10 °C for 2 h, filtered out, and dried under reduced pressure to give pure 3. (2R*,3R*)-4-Oxo-2,7-diphenyl-5-oxa-6-azaspiro[2.4]hept-6-ene-1,1-dicarbonitrile (3a) White solid; yield 0.90 g (72%); mp 188–190 °C. IR (KBr): 3052, 2324, 2248, 1804, 1448, 1132, 872, 764, 700, 612 cm–1. 1H NMR (300.1 MHz, DMSO-d 6): δ = 5.00 (s, 1 H, CH), 7.40–7.47 (m, 3 H, Ph), 7.50–7.66 (m, 5 H, Ph), 7.69–7.75 (m, 2 H, Ph). 13C NMR (75.5 MHz, DMSO-d 6): δ = 22.4, 40.6, 44.2, 109.1, 110.7, 125.8, 126.5, 128.4 (2 C), 128.8 (2 C), 129.0 (2 C), 129.1 (2 C), 130.0, 131.6, 163.1, 168.4. MS (EI, 70 eV): m/z (%) = 313 (3) [M+], 268 (11), 191 (10), 179 (54), 166 (60), 139 (44), 129 (75), 103 (18), 77 (100), 51 (87). Anal. Calcd for C19H11N3O2: C, 72.84; H, 3.54; N, 13.41. Found: C, 72.78; H, 3.64; N, 13.46. (2R*,3R*)-2-(4-Nitrophenyl)-4-oxo-7-phenyl-5-oxa-6-azaspiro[2.4]hept-6-ene-1,1-dicarbonitrile (3d) White solid; yield 1.07 g (75%); mp 175–177 °C. IR (KBr): 2924, 2340, 2252, 1804, 1520, 1352, 1136, 872, 764, 692 cm–1. 1H NMR (300.1 MHz, DMSO-d 6): δ = 5.19 (s, 1 H, CH), 7.50–7.66 (m, 3 H, Ph), 7.68–7.74 (m, 2 H, Ph), 8.23 (d, J = 8.6 Hz, 2 H, Ar), 8.37 (d, J = 8.6 Hz, 2 H, Ar). 13C NMR (75.5 MHz, DMSO-d 6): δ = 22.6, 39.5, 40.0, 108.9, 110.3, 123.2 (2 С), 125.8, 128.8 (2 С), 129.0 (2 С), 131.7, 131.9 (2 С), 134.1, 147.8, 162.9, 168.8. MS (EI, 70 eV): m/z (%) = 358 (1) [M+], 267 (4), 207 (31), 179 (91), 165 (16), 129 (84), 103 (82), 77 (100), 51 (83). Anal. Calcd for C19H10N4O4: C, 72.84; H, 3.54; N, 13.41. Found: C, 63.77; H, 2.75; 15.70. (2R*,3R*)-7-(4-Chlorophenyl)-2-(4-nitrophenyl)-4-oxo-5-oxa-6-azaspiro[2.4]hept-6-ene-1,1-dicarbonitrile (3i) White solid; yield 1.44 g (92%); mp 189–191 °C. IR (KBr): 3048, 2336, 2250, 1796, 1576, 1524, 1356, 1088, 852, 740 cm–1. 1H NMR (300.1 MHz, DMSO-d 6): δ = 5.31 (s, 1 H, CH), 7.65 (d, J = 8.4 Hz, 2 H, Ar), 7.76 (d, J = 8.4 Hz, 2 H, Ar), 7.98 (d, J = 8.3 Hz, 2 H, Ar), 8.30 (d, J = 8.3 Hz, 2 H, Ar). 13C NMR (75.5 MHz, DMSO-d 6): δ = 22.6, 23.4, 39.9, 108.8, 110.8, 123.2 (2 C), 124.7, 129.0 (2 C), 130.6 (2 C), 131.0, 131.5 (2 C), 162.2, 168.7. MS (EI, 70 eV): m/z (%) = 392 (1) [M+], 302 (2), 267 (2), 213 (43), 163 (27), 137 (44), 99 (28), 75 (54), 44 (76), 30 (100). Anal. Calcd for C19H9ClN4O4: C, 58.10; H, 2.31; Cl, 9.03; N, 14.27. Found: C, 58.08; H, 2.36; Cl, 9.06; N, 14.22.
- 13 Crystal Data for 3f C19H9FN4O4 (M = 376.30 g·mol–1): monoclinic, space group P21/n (no. 14), a = 15.47733(19) Å, b = 9.22402(10) Å, c = 12.46236(14) Å, β = 89.9765(10)°, V = 1779.17(4) Å3, Z = 4, T = 298 K, μ(Cu Kα1) = 0.926 mm–1, D calc = 1.405 g·cm–3. At average Δd of 0.01 Å (K1 = 44) the refinement converged to Rp/RP′/ RWP/ RWP′/RBragg values of 3.384/7.663/4.545/8.187/1.514% with Rexp/Rexp′ of 0.856/1.543%, GOF = 5.307. CCDC 1454070 contains the supplementary crystallographic data for compound 3f. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures.
For reviews, see: